Table 1. Tumor types showing the strongest evidence for familial occurrence.

Topography	Morphology	Cluster score	p-value*	Number of patients in FCR	Number of clusters**	Number of patients in clusters**	Suggestive predisposition gene
central nervous system	hemangioblastoma	4.98	2.77E−14	141	5	13	VHL
thyroid gland	medullary carcinoma	3.55	7.86E−21	335	9	22	RET
Skin	Kaposi sarcoma	1.91	2.05E−13	537	9	19
Pancreas	neuroendocrine carcinoma	1.40	2.75E−06	386	5	10	MEN1, RET
Kidney	nephroblastoma	1.26	5.98E−06	428	5	10	WT1
small intestine	neuroendocrine carcinoma	0.98	1.19E−09	1154	10	21
hematopoetic and reticuloendothelialsystem	myelosclerosis	0.69	2.75E−09	2186	14	28
vulva and vagina	squamous cell neoplasms and carcinoma	0.63	1.37E−10	3092	17	36
mesothelium	mesothelioma	0.62	3.49E−06	1750	10	20
Breast	mucinous and mucinous cystic tumor	0.57	2.45E−07	2564	13	27
thyroid gland	papillary adenocarcinoma	0.56	2.77E−20	7863	41	82
central nervous system	neurofibroma	0.55	1.02E−05	2062	9	21	NF1
central nervous system	neoplasm malignant	0.51	1.89E−05	2346	11	22
hematopoetic and reticuloendothelialsystem	polycythemia vera	0.50	6.07E−05	2173	10	20
hematopoetic and reticuloendothelialsystem	chronic lymphatic leukemia, b-cell	0.48	3.37E−13	7478	31	66
Kidney	neoplasm malignant	0.47	1.20E−05	3015	13	26
lymph node	Hodgkin lymphoma	0.46	2.77E−09	5499	22	47
esophagus	squamous cell neoplasms and carcinoma	0.45	8.37E−09	5514	23	46
Prostate	epithelial neoplasm and carcinoma	0.44	2.82E−05	3187	13	26
Lip	squamous cell neoplasms and carcinoma	0.35	1.04E−05	7167	22	46

^*Poisson distribution, two-sided test with 95% confidence level, p-values adjusted with FDR for multiple comparisons** CI-low ≥1.